Holen Sie sich die Stockscreener-App
21.56
1.42%
-0.31
Schlusskurs vom Vortag:
$21.87
Offen:
$21.61
24-Stunden-Volumen:
278.23K
Relative Volume:
0.57
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-11.41
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-0.42%
1M Leistung:
+1.22%
6M Leistung:
-2.22%
1J Leistung:
-7.78%
1-Tages-Spanne:
$21.38
$22.24
1-Wochen-Bereich:
$21.12
$24.38
52-Wochen-Spanne:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Vergleichen Sie ELVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.56 | 1.28B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. a good long term investmentMassive wealth growth - jammulinksnews.com
What drives Enliven Therapeutics Inc. stock priceLightning-fast capital gains - jammulinksnews.com
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser
What analysts say about Enliven Therapeutics Inc. stockTriple-digit growth rates - jammulinksnews.com
Enliven Therapeutics Inc. Stock Analysis and ForecastTremendous growth potential - Autocar Professional
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Will Enliven Therapeutics Inc. stock split in the near futureTop Performing Low Risk Stocks - Newser
Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $41.20 - Defense World
Enliven Therapeutics Breaks Above 200-Day Moving AverageBullish for ELVN - Nasdaq
Enliven Therapeutics COO Patel sells shares worth $131950 By Investing.com - Investing.com Canada
Enliven Therapeutics COO Patel sells shares worth $131950 - Investing.com
HC Wainwright Brokers Increase Earnings Estimates for ELVN - Defense World
(ELVN) Long Term Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study - TipRanks
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade - Defense World
Enliven Therapeutics stock price target raised to $48 from $40 at H.C. Wainwright - Investing.com Canada
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer? - TipRanks
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study - TipRanks
GAMMA Investing LLC Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Appoints New Directors at Annual Meeting - TipRanks
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ - Asianet Newsable
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.20 Average Target Price from Brokerages - Defense World
Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):